+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.

Age: 18Years - 60YearsAll GendersPhase 3
83 locations
E

Actively Recruiting

Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.

Age: 18Years - 60YearsAll GendersPhase 3
90 locations